跳至主要内容
临床试验/NCT01196403
NCT01196403Unknown2 期

Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer.

Wales Cancer Trials Unit8 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2009年1月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
92
试验地点
8
主要终点
Percentage of patients who consent to be randomized

研究概览

简要总结

RATIONALE: Minimal-access surgery uses a smaller opening in the body to remove the tumor than is used in standard surgery. It is not yet known whether minimal-access surgery to remove the bladder is more effective than standard surgery to remove the bladder in treating patients with bladder cancer.

PURPOSE: This randomized phase II trial is studying standard surgery to see how well it works compared with minimal-access surgery in treating patients with bladder cancer.

详细描述

OBJECTIVES:

Primary

  • To determine the feasibility of randomizing patients with bladder cancer to undergo an open cystectomy versus a minimal-access cystectomy (laparoscopic or robotic cystectomy).

Secondary

  • To assess the safety and efficacy of laparoscopic or robotic cystectomy and the reasons for non-acceptance of randomization.
  • To collect safety and toxicity data, including measures of postoperative morbidity and surgical complications. (Exploratory)
  • To investigate anatomical lymph node dissection (an indicator for oncological clearance) and completeness of cancer surgery. (Exploratory)
  • To determine the quality of life of these patients using EORTC QLQ-C30 and EORTC QLQ-BLM30 questionnaires. (Exploratory)

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Histopathologically confirmed bladder cancer, including any of the following cell types:
  • Urothelial cell (transitional cell) carcinoma
  • Squamous cell carcinoma
  • Adenocarcinoma
  • Stage pT1, pT2, or pT3 disease OR mobile bladder mass on bimanual examination under anesthesia
  • No enlarged nodes or distant metastases on CT or MRI scan of the abdomen and pelvis
  • No upper urinary tract disease
  • PATIENT CHARACTERISTICS:
  • American Society of Anesthesiologist (ASA) status 1-3
  • Life expectancy > 24 months
  • Not pregnant or nursing
  • Negative pregnancy test
  • No concurrent disease that would render the patient unsuitable for the trial
  • No presence of urosepsis
  • PRIOR CONCURRENT THERAPY:
  • May have received prior neoadjuvant chemotherapy provided study surgery is performed between 3 and 10 weeks from the date of the completion of chemotherapy treatment

排除标准

  • 未提供

结局指标

主要结局

Percentage of patients who consent to be randomized

次要结局

  • Potential barriers to randomization via semistructured qualitative interviews with patients who consent to registration and do not accept randomization
  • Potential factors relating to non-registration of patients who are eligible for inclusion but have not been registered based on review of anonymous screening logs
  • Safety and efficacy
  • Quality of life data measuring return to normal activities (physical, social, and occupational)

研究者

发起方
Wales Cancer Trials Unit
申办方类型
Other

研究点 (8)

Loading locations...

相似试验